Passweg, JR, Baldomero, H, Gratwohl, A, Bregni, M, Cesaro, S, Dreger, P, et al. The EBMT activity survey: 1990–2010. Bone Marrow Transplantation. 2012;47(7):906–23.CrossRefGoogle ScholarPubMed

Passweg, JR, Baldomero, H, Bregni, M, Cesaro, S, Dreger, P, Duarte, RF, et al. Hematopoietic SCT in Europe: data and trends in 2011. Bone Marrow Transplantation. 2013;48(9):1161–7.CrossRefGoogle ScholarPubMed

Pasquini, MC,Wang, Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides. 2013.Google Scholar

Horan, JT, Logan, BR, Agovi-Johnson, MA, Lazarus, HM, Bacigalupo, AA, Ballen, KK, et al. Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made? Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2011;29(7):805–13.CrossRefGoogle Scholar

Gooley, TA, Chien, JW, Pergam, SA, Hingorani, S, Sorror, ML, Boeckh, M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. The New England Journal of Medicine. 2010;363(22):2091–101.CrossRefGoogle ScholarPubMed

Luger, SM, Ringden, O, Zhang, MJ, Perez, WS, Bishop, MR, Bornhauser, M, et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplantation. 2012;47(2):203–11.CrossRefGoogle ScholarPubMed

Chang, YJ, Huang, XJ. Donor lymphocyte infusions for relapse after allogeneic transplantation: when, if and for whom? Blood Reviews. 2013;27(1):55–62.CrossRefGoogle Scholar

Bleakley, M, Riddell, SR. Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia. Immunology and Cell Biology. 2011;89(3):396–407.CrossRefGoogle ScholarPubMed

Norde, WJ, Overes, IM, Maas, F, Fredrix, H, Vos, JC, Kester, MG, et al. Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1-reactive cytotoxic T cells. Blood. 2009;113(10):2312–23.CrossRefGoogle ScholarPubMed

Warren, EH, Fujii, N, Akatsuka, Y, Chaney, CN, Mito, JK, Loeb, KR, et al. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood. 2010;115(19):3869–78.CrossRefGoogle Scholar

Rezvani, K, Yong, AS, Mielke, S, Savani, BN, Musse, L, Superata, J, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008;111(1):236–42.CrossRefGoogle ScholarPubMed

Oka, Y, Tsuboi, A, Taguchi, T, Osaki, T, Kyo, T, Nakajima, H, et al. Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proceedings of the National Academy of Sciences of the USA. 2004;101(38):13885–90.Google ScholarPubMed

Van Tendeloo, VF, Van de Velde, A, Van Driessche, A, Cools, N, Anguille, S, Ladell, K, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination. Proceedings of the National Academy of Sciences of the USA. 2010;107(31):13824–9.Google ScholarPubMed

Miller, JS, Soignier, Y, Panoskaltsis-Mortari, A, McNearney, SA, Yun, GH, Fautsch, SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8):3051–7.CrossRefGoogle ScholarPubMed

Bashey, A, Medina, B, Corringham, S, Pasek, M, Carrier, E, Vrooman, L, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009;113(7):1581–8.CrossRefGoogle ScholarPubMed

Yanada, M, Matsuo, K, Emi, N, Naoe, T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer. 2005;103(8):1652–8.CrossRefGoogle ScholarPubMed

Cornelissen, JJ, van Putten, WL, Verdonck, LF, Theobald, M, Jacky, E, Daenen, SM, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood. 2007;109(9):3658–66.CrossRefGoogle Scholar

Koreth, J, Schlenk, R, Kopecky, KJ, Honda, S, Sierra, J, Djulbegovic, BJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA: The Journal of the American Medical Association. 2009;301(22):2349–61.CrossRefGoogle ScholarPubMed

Burnett, AK, Wheatley, K, Goldstone, AH, Stevens, RF, Hann, IM, Rees, JH, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. British Journal of Haematology. 2002;118(2):385–400.CrossRefGoogle ScholarPubMed

Sorror, ML, Maris, MB, Storb, R, Baron, F, Sandmaier, BM, Maloney, DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–9.CrossRefGoogle ScholarPubMed

Sorror, ML, Sandmaier, BM, Storer, BE, Maris, MB, Baron, F, Maloney, DG, et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2007;25(27):4246–54.CrossRefGoogle ScholarPubMed

Gratwohl, A, Stern, M, Brand, R, Apperley, J, Baldomero, H, de Witte, T, et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer. 2009;115(20):4715–26.CrossRefGoogle ScholarPubMed

Armand, P, Kim, HT, Zhang, MJ, Perez, WS, Dal Cin, PS, Klumpp, TR, et al. Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2012;18(2):280–8.CrossRefGoogle ScholarPubMed

Cornelissen, JJ, Breems, D, van Putten, WL, Gratwohl, AA, Passweg, JR, Pabst, T, et al. Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2012;30(17):2140–6.CrossRefGoogle ScholarPubMed

Goldman, JM, Gale, RP. What does MRD in leukemia really mean? Leukemia. 2014;28(5):1131.CrossRefGoogle ScholarPubMed

Walter, RB, Buckley, SA, Pagel, JM, Wood, BL, Storer, BE, Sandmaier, BM, et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood. 2013;122(10):1813–21.Google ScholarPubMed

Appelbaum, FR. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia. Best Practice & Research Clinical Haematology. 2013;26(3):279–84.CrossRefGoogle ScholarPubMed

Patel, JP, Gonen, M, Figueroa, ME, Fernandez, H, Sun, Z, Racevskis, J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. The New England Journal of Medicine. 2012;366(12):1079–89.CrossRefGoogle ScholarPubMed

Ley, TJ, Ding, L, Walter, MJ, McLellan, MD, Lamprecht, T, Larson, DE, et al. DNMT3A mutations in acute myeloid leukemia. The New England Journal of Medicine. 2010;363(25):2424–33.CrossRefGoogle ScholarPubMed

Allen, C, Hills, RK, Lamb, K, Evans, C, Tinsley, S, Sellar, R, et al. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. Leukemia. 2013;27(9):1891–901.CrossRefGoogle ScholarPubMed

Paschka, P, Du, J, Schlenk, RF, Gaidzik, VI, Bullinger, L, Corbacioglu, A, et al. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). Blood. 2013;121(1):170–7.CrossRefGoogle Scholar

Kurosawa, S, Yamaguchi, T, Miyawaki, S, Uchida, N, Sakura, T, Kanamori, H, et al. Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse. Haematologica. 2010;95(11):1857–64.CrossRefGoogle ScholarPubMed

Duval, M, Klein, JP, He, W, Cahn, JY, Cairo, M, Camitta, BM, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2010;28(23):3730–8.CrossRefGoogle ScholarPubMed

Burnett, AK, Goldstone, A, Hills, RK, Milligan, D, Prentice, A, Yin, J, et al. Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2013;31(10):1293–301.CrossRefGoogle Scholar

San Miguel, JF, Martinez, A, Macedo, A, Vidriales, MB, Lopez-Berges, C, Gonzalez, M, et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood. 1997;90(6):2465–70.CrossRefGoogle ScholarPubMed

Kern, W, Voskova, D, Schoch, C, Hiddemann, W, Schnittger, S, Haferlach, T. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood. 2004;104(10):3078–85.Google ScholarPubMed

Terwijn, M, van Putten, WL, Kelder, A, van der Velden, VH, Brooimans, RA, Pabst, T, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2013;31(31):3889–97.CrossRefGoogle ScholarPubMed

Buccisano, F, Maurillo, L, Del Principe, MI, Del Poeta, G, Sconocchia, G, Lo-Coco, F, et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood. 2012;119(2):332–41.CrossRefGoogle ScholarPubMed

Rubnitz, JE, Inaba, H, Dahl, G, Ribeiro, RC, Bowman, WP, Taub, J, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. The Lancet Oncology. 2010;11(6):543–52.CrossRefGoogle ScholarPubMed

Fang, M, Storer, B, Wood, B, Gyurkocza, B, Sandmaier, BM, Appelbaum, FR. Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation. Cancer. 2012;118(9):2411–9.CrossRefGoogle ScholarPubMed

Copelan, EA, Hamilton, BK, Avalos, B, Ahn, KW, Bolwell, BJ, Zhu, X, et al. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013;122(24):3863–70.CrossRefGoogle ScholarPubMed

Bredeson, C, LeRademacher, J, Kato, K, Dipersio, JF, Agura, E, Devine, SM, et al. Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood. 2013;122(24):3871–8.CrossRefGoogle ScholarPubMed

Nagler, A, Rocha, V, Labopin, M, Unal, A, Ben Othman, T, Campos, A, et al. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen–a report from the acute leukemia working party of the European group for blood and marrow transplantation. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2013;31(28):3549–56.CrossRefGoogle ScholarPubMed

Bacigalupo, A, Ballen, K, Rizzo, D, Giralt, S, Lazarus, H, Ho, V, et al. Defining the intensity of conditioning regimens: working definitions. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2009;15(12):1628–33.CrossRefGoogle ScholarPubMed

Aoudjhane, M, Labopin, M, Gorin, NC, Shimoni, A, Ruutu, T, Kolb, HJ, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia. 2005;19(12):2304–12.CrossRefGoogle Scholar

Scott, BL, Pasquini, MC, Logan, B, et al. Results of a phase III randomized, multi-center study of allogeneic stem cell transplantation after high versus reduced intensity conditioning in patients with myelodysplastic syndrome or acute myeloid leukemia: Blood and Marrow Transplant Clinical Trials network (BMT CTN) 0901. Blood. 2015;126.CrossRefGoogle Scholar

Bensinger, WI, Martin, PJ, Storer, B, Clift, R, Forman, SJ, Negrin, R, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. The New England Journal of Medicine. 2001;344(3):175–81.CrossRefGoogle ScholarPubMed

Stem Cell Trialists’ Collaborative G. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2005;23(22):5074–87.Google Scholar

Anasetti, C, Logan, BR, Lee, SJ, Waller, EK, Weisdorf, DJ, Wingard, JR, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. The New England Journal of Medicine. 2012;367(16):1487–96.CrossRefGoogle ScholarPubMed

Appelbaum, FR. Pursuing the goal of a donor for everyone in need. The New England Journal of Medicine. 2012;367(16):1555–6.CrossRefGoogle ScholarPubMed

Walter, RB, Pagel, JM, Gooley, TA, Petersdorf, EW, Sorror, ML, Woolfrey, AE, et al. Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission. Leukemia. 2010;24(7):1276–82.CrossRefGoogle ScholarPubMed

Imahashi, N, Suzuki, R, Fukuda, T, Kakihana, K, Kanamori, H, Eto, T, et al. Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk AML in first CR. Bone Marrow Transplantation. 2013;48(1):56–62.CrossRefGoogle ScholarPubMed

Gupta, V, Tallman, MS, He, W, Logan, BR, Copelan, E, Gale, RP, et al. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood. 2010;116(11):1839–48.CrossRefGoogle ScholarPubMed

Gragert, L, Eapen, M, Williams, E, Freeman, J, Spellman, S, Baitty, R, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. The New England Journal of Medicine. 2014;371(4):339–48.CrossRefGoogle ScholarPubMed

Lee, SJ, Klein, J, Haagenson, M, Baxter-Lowe, LA, Confer, DL, Eapen, M, et al. High-resolution donor-recipient HLA-matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110(13):4576–83.Google Scholar

Barker, JN, Scaradavou, A, Stevens, CE. Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. Blood. 2010;115(9):1843–9.CrossRefGoogle ScholarPubMed

Eapen, M, Klein, JP, Sanz, GF, Spellman, S, Ruggeri, A, Anasetti, C, et al. Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. The Lancet Oncology. 2011;12(13):1214–21.CrossRefGoogle Scholar

Ruggeri, A, Sanz, G, Bittencourt, H, Sanz, J, Rambaldi, A, Volt, F, et al. Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT. Leukemia. 2014;28(4):779–86.CrossRefGoogle ScholarPubMed

Scaradavou, A, Brunstein, CG, Eapen, M, Le-Rademacher, J, Barker, JN, Chao, N, et al. Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. Blood. 2013;121(5):752–8.CrossRefGoogle ScholarPubMed

Verneris, MR, Brunstein, CG, Barker, J, MacMillan, ML, DeFor, T, McKenna, DH, et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood. 2009;114(19):4293–9.CrossRefGoogle ScholarPubMed

Wagner, JE Jr., Eapen, M, Carter, S, Wang, Y, Schultz, KR, Wall, DA, et al. One-unit versus two-unit cord-blood transplantation for hematologic cancers. The New England Journal of Medicine. 2014;371(18):1685–94.CrossRefGoogle ScholarPubMed

Ciceri, F, Labopin, M, Aversa, F, Rowe, JM, Bunjes, D, Lewalle, P, et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood. 2008;112(9):3574–81.CrossRefGoogle ScholarPubMed

Huang, XJ, Liu, DH, Liu, KY, Xu, LP, Chen, H, Han, W, et al. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2009;15(2):257–65.CrossRefGoogle ScholarPubMed

Champlin, RE, Passweg, JR, Zhang, MJ, Rowlings, PA, Pelz, CJ, Atkinson, KA, et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood. 2000;95(12):3996–4003.Google ScholarPubMed

Baron, F, Labopin, M, Blaise, D, Lopez-Corral, L, Vigouroux, S, Craddock, C, et al. Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation. 2014;49(3):389–96.CrossRefGoogle ScholarPubMed

Bayraktar, UD, de Lima, M, Saliba, RM, Maloy, M, Castro-Malaspina, HR, Chen, J, et al. Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2013;19(6):898–903.CrossRefGoogle ScholarPubMed

Pavletic, SZ, Kumar, S, Mohty, M, de Lima, M, Foran, JM, Pasquini, M, et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2010;16(7):871–90.CrossRefGoogle Scholar

Fung, HC, Stein, A, Slovak, M, O’Donnell, M R, Snyder, DS, Cohen, S, et al. A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2003;9(12):766–71.CrossRefGoogle ScholarPubMed

Ferrant, A, Labopin, M, Frassoni, F, Prentice, HG, Cahn, JY, Blaise, D, et al. Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood. 1997;90(8):2931–8.Google Scholar

Tallman, MS, Dewald, GW, Gandham, S, Logan, BR, Keating, A, Lazarus, HM, et al. Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. Blood. 2007;110(1):409–17.CrossRefGoogle ScholarPubMed

Brunet, S, Labopin, M, Esteve, J, Cornelissen, J, Socie, G, Iori, AP, et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2012;30(7):735–41.CrossRefGoogle ScholarPubMed

Randolph, SS, Gooley, TA, Warren, EH, Appelbaum, FR, Riddell, SR. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood. 2004;103(1):347–52.CrossRefGoogle ScholarPubMed

Goldstone, AH, Burnett, AK, Wheatley, K, Smith, AG, Hutchinson, RM, Clark, RE, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98(5):1302–11.CrossRefGoogle Scholar

Buyse, M, Squifflet, P, Lange, BJ, Alonzo, TA, Larson, RA, Kolitz, JE, et al. Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood. 2011;117(26):7007–13.CrossRefGoogle ScholarPubMed

de Lima, M, Giralt, S, Thall, PF, de Padua, Silva L, Jones, RB, Komanduri, K, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer. 2010;116(23):5420–31.CrossRefGoogle ScholarPubMed

Platzbecker, U, Wermke, M, Radke, J, Oelschlaegel, U, Seltmann, F, Kiani, A, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia. 2012;26(3):381–9.CrossRefGoogle ScholarPubMed

Metzelder, SK, Schroeder, T, Finck, A, Scholl, S, Fey, M, Gotze, K, et al. High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia. 2012;26(11):2353–9.CrossRefGoogle ScholarPubMed

Keilholz, U, Letsch, A, Busse, A, Asemissen, AM, Bauer, S, Blau, IW, et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood. 2009;113(26):6541–8.CrossRefGoogle ScholarPubMed

Rezvani, K, Yong, AS, Mielke, S, Jafarpour, B, Savani, BN, Le, RQ, et al. Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies. Haematologica. 2011;96(3):432–40.CrossRefGoogle ScholarPubMed

Gale, RP and Fuchs, EJ. Is there really a specific graft-versus-leukaemia effect? Bone Marrow Transplant. 2016; Nov; 51(11):1413–15.CrossRefGoogle ScholarPubMed

Deol, A, Sengsayadeth, S, Ahn, KW, et al. Does FLT 3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer. 2016;122(19):3005–14.CrossRefGoogle Scholar

Papaemmanuil, E, Gerstung, M, Bullinger, L, et al. Genomic classification and prognosis in acute myeloid leukemia. New England Journal of Medicine. 2016;374(23):2209–21.CrossRefGoogle ScholarPubMed

Schlenk, RF, Kayser, S, Bullinger, L, et al. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. Blood. 2014;124(23):3441–9.CrossRefGoogle ScholarPubMed

Linch, DC, Hills, RK, Burnett, AK, et al. Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia. Blood. 2014;124(2):273–6.CrossRefGoogle ScholarPubMed

Krug, U, Berdel, WE, Gale, RP. Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia. Leukemia. 2016;30(6):1230–6.CrossRefGoogle Scholar

Sanz, J, Gale, RP. One or two umbilical cord blood cell units? Caveat emptor. Bone Marrow Transplantation. In press.Google Scholar

Bacigalupo, A, Lamparelli, T, Barisione, G, et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2006;12:560–5.CrossRefGoogle ScholarPubMed

Finke, J, Bethge, WA, Schmoor, C, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology. 2009;10(9):855–64.CrossRefGoogle ScholarPubMed

Kroger, N, Solano, C, Wolschke, C, et al. Antilymphocyte globulin for prevention of chronic graft-versus-host-disease. New England Journal of Medicne. 2016;374(1):43–53. PMID: 26735993.CrossRefGoogle ScholarPubMed

Walker, I, Panzarella, T, Couban, S, et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients witih haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicenter trial. Lancet Oncology. 2016;17:164–73.CrossRefGoogle Scholar

Ivey, A, Hills, RK, Simpson, MA, et al. Assessment of minimal residual disease in standard-risk AML. New England Journal of Medicine. 2016;374(5):422–33.CrossRefGoogle ScholarPubMed

Othus, M, Estey, E, Gale, RP. Assessment of minimal residual disease in standard-risk AML. New England Journal of Medicine. 2016;375(6): e9.Google ScholarPubMed

Adults with acute myeloid leukaemia or high-risk myelodysplastic syndrome (AML 19): a randomized, controlled, open label Phase III trial. Retrieved December 21, 2016, from www.isrctn.com/ISRCTN78449203.Google Scholar

Milano, F, Gooley, T, Wood, B, et al. Cord-blood transplantation in patients with minimal residual disease. New England Journal of Medicine. 2016;375(10):944–53.CrossRefGoogle ScholarPubMed